Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azithromycin
Drug ID BADD_D00203
Description Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides [A174175]. In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine]. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.[A192546]
Indications and Usage For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal
Marketing Status Prescription; Discontinued
ATC Code J01FA10; S01AA26
DrugBank ID DB00207
KEGG ID D06390
MeSH ID D017963
PubChem ID 447043
TTD Drug ID D03HJK
NDC Product Code 53002-0470; 50111-787; 68071-2672; 70710-1458; 53002-5228; 68071-4795; 0781-5789; 68788-8125; 70518-2708; 50090-4720; 71610-001; 0409-0144; 50090-2509; 62332-251; 63629-8034; 68071-1528; 63629-7784; 63629-8251; 50090-4458; 68071-4773; 59651-008; 16571-695; 42806-147; 70710-1457; 59762-3051; 55150-174; 68788-7659; 71205-196; 50090-4721; 70518-0713; 68071-4902; 55700-731; 65862-641; 24658-706; 72189-314; 70518-2562; 50090-5376; 68071-4785; 63187-189; 76420-006; 0093-2027; 0781-5793; 53002-6221; 68071-4786; 53002-2230; 70518-3217; 71205-158; 70771-1424; 68071-4711; 71205-503; 50090-5283; 42291-082; 64679-961; 71205-645; 63187-169; 63187-594; 64679-964; 68788-8124; 65862-642; 42291-084; 55695-002; 71205-253; 70518-2433; 68788-7549; 68071-2507; 76420-213; 71205-519; 53002-2228; 68788-7066; 68071-4779; 63187-093; 63629-8311; 61294-9990; 59762-3130; 69306-250; 68071-4364; 42291-083; 0781-8089; 71610-381; 61919-555; 59651-007; 68071-2543; 53002-2225; 50090-5366; 68071-5035; 42806-151; 50111-788; 62332-253; 46708-253; 69452-173; 64679-962; 59762-3140; 70518-3254; 68071-2297; 45865-536; 60760-502; 68788-7598; 50090-0984; 63187-007; 59762-3120; 68071-5058; 68071-4812; 71335-1755; 69452-172; 71205-216; 68071-1527; 68788-7307; 68071-4774; 53002-2231; 68788-7507; 63187-622; 0093-2026; 71205-021; 50090-0983; 60760-808; 68071-5238; 43386-471; 42806-149; 71335-1252; 16571-696; 70710-1460; 50111-789; 53002-2224; 71205-424; 62756-512; 24658-708; 72189-088; 38779-2246; 59762-2198; 72189-087; 68071-5082; 59762-3110; 70518-0784; 55700-784; 42806-150; 69452-171; 50090-2491; 72189-093; 55700-852; 70710-1459; 0781-8090; 0781-8091; 68071-2266; 70771-1425; 46708-058; 53002-5221; 70518-3169; 70771-1422; 70518-0599; 53002-0473; 70771-1423; 65427-310; 68071-5170; 68071-2622; 53002-0472; 68071-2529; 71335-1195; 62332-252; 72189-015; 68788-7636; 63187-604; 68071-4255; 68071-4976; 46708-057; 55695-003; 71205-566; 43386-470
Synonyms Azithromycin | Azythromycin | Sumamed | Toraseptol | Vinzam | CP-62993 | CP 62993 | CP62993 | Zithromax | Azitrocin | Azadose | Ultreon | Zitromax | Azithromycin Dihydrate | Dihydrate, Azithromycin | Azithromycin Monohydrate | Monohydrate, Azithromycin | Goxal | Zentavion
Chemical Information
Molecular Formula C38H72N2O12
CAS Registry Number 83905-01-5
SMILES CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C) C)O)(C)O)C)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic failure09.01.03.0020.000007%
Hepatic function abnormal09.01.02.001--Not Available
Hepatic necrosis09.01.07.002--
Hepatic steatosis14.08.04.005; 09.01.07.0030.000025%Not Available
Hepatitis09.01.07.0040.000063%Not Available
Hepatocellular injury09.01.07.0080.000101%Not Available
Hepatomegaly09.01.05.0010.000025%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hostility19.05.01.003--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkinesia17.01.02.008--Not Available
Hyperpyrexia08.05.02.0020.000007%Not Available
Hypersensitivity10.01.03.0030.000139%
Hypertension24.08.02.001--
Hyperthermia12.05.01.002; 08.05.01.0010.000025%Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypokalaemia14.05.03.002--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000025%
Infection11.01.08.002--Not Available
Inflammatory bowel disease07.08.01.0160.000038%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Instillation site pain08.02.01.008; 12.07.01.008--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.000050%Not Available
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000025%Not Available
Jaundice cholestatic09.01.01.0050.000025%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 12 Pages